Company / SG&A Expense
Idexx Laboratories SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$404.8M
FY2025
5-year range
$309.7M / $442.3M
FY2021-FY2025
Trend
-8.5%
vs FY2024
Sector context
#76 of 152
Health Care
What the data says
At $405M, Idexx Laboratories's sg&a expense ranks #77 of 152 in the Health Care sector. Increased from $336M to $405M over the past 2 years.
Based on SEC 10-K filings.
$405M in FY2025 with a 5-year CAGR of +6.1%.
Increased from $336M to $405M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +7.5%
- 5-Year CAGR
- +6.1%
- 10-Year CAGR
- -
Sector benchmark
#77 of 152 in Health CareTop 50% of 152This company $404.8M Sector average $182.7B
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.1%, indicating consistent growth.
- In FY2025, sg&a expense decreased 8.5% year-over-year.
- Ranks #76 out of 152 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $404.8M | -8.5% |
| FY2024 | $442.3M | +31.7% |
| FY2023 | $335.8M | +2.9% |
| FY2022 | $326.2M | +5.4% |
| FY2021 | $309.7M | +2.9% |
| FY2020 | $300.8M | +15.1% |
| FY2019 | $261.3M | +6.7% |
| FY2018 | $244.9M | +10.9% |
| FY2017 | $220.9M | +6.7% |
| FY2016 | $207.0M | +13.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026